Stanzani M, Colombo L, Altomare S, Pagnozzi G, Barbieri C, Bruschi R, Pietrasanta E
Day-Hospital, Ospedale S. Paolo, Milano.
Minerva Cardioangiol. 1993 Oct;41(10):465-8.
The authors examine a series of 20 patients suffering from AOCP (?) at Fontaine's 2nd stage treated with calciparine s.c. in a single daily dose of 12500 IU for three months. The parameters of clinical assessment of claudicatio intermittens show statistically significant increases of ILR and ILA which were not correlated to marked variations of the Windsor index. The extremely positive results in terms of the clinical trend of the disease are encouraging with a view to a more extensive application of this therapeutic approach in peripheral arterial disease of the lower limbs.
作者对20例处于Fontaine二期的AOCP（？）患者进行了研究，采用皮下注射凯时，每日单次剂量12500国际单位，持续三个月。间歇性跛行的临床评估参数显示，ILR和ILA有统计学意义的增加，且与温莎指数的显著变化无关。就疾病的临床趋势而言，这些极其积极的结果令人鼓舞，有望在下肢外周动脉疾病中更广泛地应用这种治疗方法。
